参考文献/References:
[1] Davies L, Welch HG.Current thyroid cancer trends in the United States[J].JAMA Otolaryngol Head Neck Surg, 2014, 140(4):317-322. DOI:10.1001/jamaoto.2014.1.
[2] Shaha AR.Recurrent differentiated thyroid cancer[J].Endocr Pract, 2012, 18(4):600-603. DOI:10.4158/EP12047.CO.
[3] Orita Y, Sugitani I, Matsuura M, et al.Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma[J].Surgery, 2010, 147(3):424-431. DOI:10.1016/j.surg.2009.10.009.
[4] Bechsgaard T, Lelkaitis G, Jensen KE, et al.Diagnosis of bone metastasis from thyroid carcinoma:a multidisciplinary approach[J].Acta Radiol Open, 2015, 4(11):1-3. DOI:10.1177/2058460115603248.
[5] Pittas AG, Adler M, Fazzari M, et al.Bone metastases from thyroid carcinoma:clinical characteristics and prognostic variables in one hundred forty-six patients[J].Thyroid, 2000, 10(3):261-268. DOI:10.1089/thy.2000.10.261.
[6] Lin JD, Huang MJ, Juang JH, et al.Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases[J].Thyroid, 1999, 9(12):1227-1235. DOI:10.1089/thy.1999.9.1227.
[7] Kallel F, Hamza F, Charfeddine S, et al.Clinical features of bone metastasis for differentiated thyroid carcinoma:A study of 21 patients from a Tunisian center[J].Indian J Endocrinol Metab, 2014, 18(2):185-190. DOI:10.4103/2230-8210.129109.
[8] 邱忠领.131I治疗分化型甲状腺癌骨转移的临床研究[D].苏州:苏州大学, 2010.Qiu ZL.Clinical Study of 131I for the Treatment of bone metastases from differentiated thyroid cancer[D].Suzhou:Soochow University, 2010.
[9] 杨辉, 田辉英, 李文亮, 等.核素全身骨显像在多发性骨髓瘤诊断中的应用价值[J].肿瘤影像学, 2013, 22(3):223-226.Yang H, Tian HY, Li WL, et al.Application value of whole-body scan in diagnosis of multiple myeloma[J].Oncoradiology, 2013, 22(3):223-226.
[10] Pacini F, Capezzone M, Elisei R, et al.Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment[J].J Clin Endocrinol Metab, 2002, 87(4):1499-1501. DOI:10.1210/jcem.87.4.8274.
[11] Torlontano M, Crocetti U, D’aloiso L, et al.Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer[J].Eur J Endocrinol, 2003, 148(1):19-24. DOI:10.1530/eje.0.1480019.
[12] Carril JM, Quirce R, Serrano J, et al.Total-body scintigraphy with thallium-201 and iodine-131 in the follow-up of differentiated thyroid cancer[J].J Nucl Med, 1997, 38(5):686-692.
[13] Muratet JP, Giraud P, Daver A, et al.Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma[J].J Nucl Med, 1997, 38(9):1362-1368.
[14] Fatourechi V, Hay ID, Mullan BP, et al.Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer[J].Thyroid, 2000, 10(7):573-577. DOI:10.1089/thy.2000.10.573.
[15] Souza Rosário PW, Barroso AL, Rezende LL, et al.Post I-131 therapy scanning in patients with thyroid carcinoma metastases:an unnecessary cost or a relevant contribution[J].Clin Nucl Med, 2004, 29(12):795-798.
[16] 陶衍能, 陈汉华, 韦令欣.131I治疗分化型甲状腺癌骨转移的疗效评价[J].中华全科医学, 2012, 10(12):1896-1897. DOI:10.16766/j.cnki.issn.1674-4152.2012.12.093.Tao YN, Chen HH, Wei LX.The evaluation of curative in differentiated thyroid cancer of bone metastases with the treatment of 131I[J].Chin J Gen Pract, 2012, 1012(12):1896-1897.
[17] 程旭, 李永军, 徐兆强, 等.治疗剂量131I SPECT/CT显像评价分化型甲状腺癌骨转移[J].标记免疫分析与临床, 2015, 22(11):1095-1098. DOI:10.11748/bjmy.issn.1006-1703.2015.11.007.Cheng X, Li YJ, Xu ZQ, et al.Application of 131I SPECT/CT fusion imaging for evaluation bone metastasis in patients witn DTC[J].Labeled Immunoassays Clin Med[J].2015, 22(11):1095-1098.
[18] 白青山, 秦莎娜, 张海龙, 等.SPECT/CT同机融合显像对骨转移瘤的诊断价值[J].内蒙古医学杂志, 2014, 46(1):88-89.Bai QS, Qin SN, Zhang HL, et.al.Value of SPECT/CT fusion imaging in the diagnosis of bone metastases[J].Inner Mongolia Med J, 2014, 46(1):88-89.
[19] Qiu ZL, Xue YL, Song HJ, et al.Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer[J].Nucl Med Commun, 2012, 33(12):1232-1242. DOI:10.1097/MNM.0b013e328358d9c0.
[20] Kotb MH, Omar W, El-Maghraby T, et al.The value of simultaneous co-registration of 99mTc-MDP and 131Iodine in metastatic differentiated thyroid carcinoma[J].Nucl Med Rev Cent East Eur, 2007, 10(2):98-105.
[21] 段东升, 任媛.分化型甲状腺癌骨转移临床分析[J].中国药物与临床, 2014, 14(5):662-663. DOI:10.11655/zgywylc2014.05.048.Duan DS, Ren Y, The clinical analysis of differentiated thyroid cancer of bone metastases[J].Chi Remed Clin, 2014, 14(5):662-663.
[22] Agate L, Bianchi F, Giorgetti A, et al.Detection of metastases from differentiated thyroid cancer by different imaging techniques(neck ultrasound, computed tomography and [18F]-FDG positron emission tomogr-aphy)in patients with negative post-therapeutic 131I whole-body scan and detectable serum thyroglobulin levels[J].J Endocrinol Invest, 2014, 37(10):967-972. DOI:10.1007/s40618-014-0134-1.
[23] 齐红艳, 孙逊, 安锐.骨转移瘤影像学检查方法及相关进展[J].华中科技大学学报(医学版), 2015, 44(1):121-124. DOI:10.3870/j.issn.1672-0741.2015.01.025.Qi HY, Sun X, An R.The imaging methods and progress of bone metastatic tumors[J].Acta Med Univ Sci Technol Huazhong, 2015, 44(1):121-124.
[24] Kotb MH, Omar W, El-Maghraby T, et al.The value of simultaneous co-registration of 99mTc-MDP and 131Iodine in metastatic differentiated thyroid carcinoma[J].Nucl Med Rev Cent East Eur, 2007, 10(2):98-105.
[25] 谭涛.SPECT-PET显像在分化型甲状腺癌131I治疗预后中的应用价值[J].河南外科学杂志, 2012, 18(4):12-15.Tan T.Applications of SPECT-PET in the splitting up type cancer 131I therapy prognosis of differentiated thyroid carcinoma[J].Henan J Surg, 2012, (4):12-15.
[26] 王姝, 李亚明, 李娜, 等.溶骨性骨代谢增高病灶的SPECT/CT骨显像特点及与CT表现的相关性[J].中华核医学与分子影像杂志, 2015, 35(6):466-469. DOI:10.3760/cma.j.issn.2095-2848.2015.06.011.Wang S, Li YM, Li N, et al.SPECT/CT imaging characteristic of osteolytic lesions with increased bone metabolism and its correlation with CT manifestation[J].Chin J Nuclear Med Mol Imaging, 2015, 35(6):466-469.
[27] Lopci E, Chiti A, Castellani MR, et al.Matched pairs dosimetry:124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies[J].Eur J Nucl Med Mol Imaging, 2011, 38 Suppl 1:S28-S40. DOI:10.1007/s00259-011-1772-6.
[28] Rault E, Vandenberghe S, Van Holen R, et al.Comparison of image quality of different Iodine isotopes(I-123, I-124, and I-131)[J].Cancer Biother Radiopharm, 2007, 22(3):423-30. DOI:10.1089/cbr.2006.323.
[29] Phan HT, Jager PL, Paans AM, et al.The diagnostic value of 124I-PET in patients with differentiated thyroid cancer[J].Eur J Nucl Med Mol Imaging, 2008, 35(5):958-965. DOI:10.1007/s00259-007-0660-6.
[30] Van Nostrand D, Moreau S, Bandaru VV, et al.124I positron emission tomography versus 131I planar imaging in the identification of residual thyroid tissue and/or metastasis in patients who have well-differentiated thyroid cancer[J].Thyroid, 2010, 20(8):879-883. DOI:10.1089/thy.2009.0430.
[31] 刘斌, 郭佳, 王建涛, 等.124I PET/CT在分化型甲状腺癌诊治中的应用[J].中华核医学与分子影像杂志, 2013, 33(1):71-74 DOI:10.3760/cma.j.issn.2095-2848.2013.01.021.Liu B, Guo J, Wang JT, et al.Clinical applications of 124I PET/CT in patients with differentiated thyroid carcinoma[J].Chin J Nucl Med Mol Imaging, 2013, 33(1):71-74.
[32] Capoccetti F, Criscuoli B, Rossi G, et al.The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer[J].Q J Nucl Med Mol Imaging, 2009, 53(5):536-545.
[33] 黄蕤, 匡安仁.18F-FDG正电子断层显像在分化型甲状腺癌中的应用进展[J].生物医学工程学杂志, 2014, 31(2):445-451.Huang R, Kuang AR.Application progress of 18F-FDG positron emission tomograph in differentiated thyroid cancer[J].J Biomed Eng, 2014, 31(2):445-451.
[34] Nahas Z, Goldenberg D, Fakhry C, et al.The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma[J].Laryngoscope, 2005, 115(2):237-243. DOI:10.1097/01.mlg.0000154725.00787.00.
[35] 范群, 匡安仁, 袁耿彪.18F-FDG PET显像在分化型甲状腺癌患者随访中的应用[J].现代生物医学进展, 2006, 6(9):42-46. DOI:10.3969/j.issn.1673-6273.2006.09.015.Fan Q, Kuang AR, Yuan GB.18F-FDG PET application in the differentiated thyroid cancer[J].Prog Mod Biomed, 2006, 6(9):42-46.
[36] Shon IH, Depcynzski B, Lin M, et al.Positron emission tomography in non-medullary thyroid cancer[J].ANZ J Surg, 2011, 81(3):116-124. DOI:10.1111/j.1445-2197.2010.05538.x.
[37] Treglia G, Muoio B, Giovanella L, et al.The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours:an overview[J].Eur Arch Otorhinolaryngology, 2013, 270(6):1783-1787. DOI:10.1007/s00405-012-2205-2.
[38] Riemann B, Uhrhan K, Dietlein M, et al.Diagnostic value and therapeutic impact of 18F-FDG-PET/CT in differentiated thyroid cancer.Results of a German multicentre study[J].Nuklearmedizin, 2013, 52(1):1-6. DOI:10.3413/nukmed-0489-12-03.
[39] Seo YL, Yoon DY, Baek S, et al.Detection of neck recurrence in patients with differentiated thyroid cancer:comparison of ultrasound, contrast-enhanced CT and 18F-FDG PET/CT using surgical pathology as a reference standard:(ultrasound vs.CT vs.(18)F-FDG PET/CT in recurrent thyroid cancer)[J].Eur Radiol, 2012, 22(10):2246-2254. DOI:10.1007/s00330-012-2470-x.
[40] Choi WH, Chung YA, Han EJ, et al.Clinical value of integrated[18F]fluoro-2-Deoxy-D-Glucose positron emission tomography/computed tomography in the preoperative assessment of papillary thyroid carcinoma[J].J Ultrasound Med, 2011, 30(9):1267-1273.
[41] Kim BS, Kim SJ, Kim IJ, et al.Factors associated with positive F-18 flurodeoxyglucose positron emission tomography before thyroidectomy in patients with papillary thyroid carcinoma[J].Thyroid, 2012, 22(7):725-729. DOI:10.1089/thy.2011.0031.
[42] 武凤玉, 王振光.18F-FDG PET/CT显像在甲状腺肿瘤中的应用[J].中华核医学与分子影像杂志, 2016, 36(2):192-195. DOI:10.3760/cma.j.issn.2095-2848.2016.02.023.Wu FY, Wang ZG.The application of 18F-FDG PET/CT in thyroid tumor[J].Chin J Nucl Med Mol Imaging, 2016, 36(2):192-195.
[43] 吕中伟, 朱承谟, 管梁, 等.18F-FDG PET显像与99Tcm-MDP全身骨显像诊断肿瘤远处转移的比较[J].中华核医学杂志, 2001, 21(4):209-210.Lyu ZW, Zhu CM, Guan L, et al.Comparative study of 18F-FDG PET imaging and 99Tcm-MDP whole body bone imaging in detection of remote metastasis[J].Chin J Nucl Med, 2001, 21(4):209-210.
[44] 祝安惠, 王荣福.PET/CT与全身骨显像诊断不同类型骨转移瘤的对比[J].中国医学影像技术, 2016, 32(6):944-948. DOI:10.13929/j.1003-3289.2016.06.034.Zhu AH, Wang RF.Comparison of diagnostic capability on different types of bone metastases between PET/CT and whole-body bone scan[J].Chin J Med Imaging Technol, 2016, 32(6):944-948.
[45] Raijmakers P, Temmerman OP, Saridin CP, et al.Quantification of 18F-Fluoride kinetics:evaluation of simplified methods[J].J Nucl Med, 2014, 55(7):1122-1127.D:10.2967/jnumed.113.135269.
[46] Wondergem M, Van Der Zant FM, Van Der Ploeg T, et al.A literature review of F-18-fluoride PET/CT and F-18-choline or C-11-choline PET/CT for detection of bone metastases in patients with prostate cancer[J].Nucl Med Commun, 2013, 34(10):935-945. DOI:10.1097/MNM.0b013e328364918a.
[47] Frost ML, Compston JE, Goldsmith D, et al.18F-fluoride positron emission tomography measurements of regional bone formation in hemodialysis patients with suspected adynamic bone disease[J].Calcif Tissue Int, 2013, 93(5):436-447. DOI:10.1007/s00223-013-9778-7.
[48] Schirrmeister H, Glatting G, Hetzel J, et al.Prospective evaluation of the clinical value of planar bone scans, SPECT, and F-18-labeled NaFPET in newly diagnosed lung cancer[J].J Nucl Med, 2001, 42(12):1800-1804.
[49] 张胤, 陈跃.18F-氟化钠PET/CT诊断肿瘤骨转移应用进展[J].国际放射医学核医学杂志, 2015(1):96-102. DOI:10.3760/cma.j.issn.1673-4114.2015.01.020.Zhang Y, Chen Y.Application progress of 18F-NaF PET/CT in the diagnosis of neoplasm metastases[J].Int J Radiat Med Nucl Med, 2015(1):96-102.
[50] Caldarella C, Treglia G, Giordano A, et al.When to perform positron emission tomography/computed tom ography or radionuclide bone scan in patients with recently diagnosed prostate cancer[J].Cancer Manag Res, 2013, 5:123-131. DOI:10.2147/CMAR.S34685.
[51] Tateishi U, Morita S, Taguri M, et al.A meta-analysis of 18F-Fluoride positron emission tomography for assessment of metastatic bone tumor[J].Ann Nucl Med, 2010, 24(7):523-531. DOI:10.1007/s12149-010-0393-7.
[52] 黄禾, 陈跃.18F-NaF PET/CT在骨良性病变中的临床应用与研究进展[J].中国医学影像技术, 2016, 32(3):457-460. DOI:10.13929/j.1003-3289.2016.03.035.Huang H, Chen Y.Clinical application and progresses of 18F-NaF PET/CT in benign lesions of the bones[J].Chin J Med Imaging Technol, 2016, 32(3):457-460.
[53] Chan SC, Wang HM, Ng SH, et al.Utility of 18F-fluoride PET/CT and 18F-FDG PET/CT in the detection of bony metastases in heightened-risk head and neck cancer patients[J].J Nucl Med, 2012, 53(11):1730-1735. DOI:10.2967/jnumed.112.104893.
[54] Ota N, Kato K, Iwano S, et al.Comparison of 18F-fluoride PET/CT, 18F-FDG PET/CT and bone scintigraphy (planar and SPECT)in detection of bone metastases of differentiated thyroid cancer:a pilot study[J].Br J Radiol, 2014, 87(1034):20130444. DOI:10.1259/bjr.20130444.
[55] Harisankar CN, Agrawal K, Bhattacharya A, et al.F-18 fluoro-deoxy-glucose and F-18 Sodium fluoride cocktail PET/CT scan in patients with breast cancer having equivocal bone SPECT/CT[J].Indian J Nucl Med, 2014, 29(2):81-86. DOI:10.4103/0972-3919.130287.
[56] 吉蘅山, 孙传金, 朱虹, 等.18F-NaF PET/CT与99Tcm-MDP骨显像诊断骨转移瘤价值的对比研究[J].东南国防医药, 2015, 17(6):642-644. DOI:10.3969/j.issn.1672-271X.2015.06.025.Ji HS, Sun CJ, Zhu H.The value of 18F-NaF PET/CT and 99mTc-MDP 18F-NaF bone imaging in the diagnosis of bone metastases[J].Military Med J Southeast China, 2015, 17(6):642-644.
[57] Petersen H, Ogren M, H?ilund-Carlsen PF.Fluoride-positron emission tomography/computed tomography for differential diagnosis in suspected bone metastasis[J].Ugeskr Laeger, 2010, 172(20):1538-1539.
[58] Aparici CM, Win AZ.Use of NaF-18-Positron emission tomography/computed tomography in the detection of bone metastasis from papillary renal cell carcinoma[J].World J Nucl Med, 2014, 13(2):135-137. DOI:10.4103/1450-1147.139146.
[59] Fischer DR.Musculoskeletal imaging using fluoride PET[J].Semin Nucl Med, 2013, 43(6):427-433. DOI:10.1053/j.semnuclmed.2013.06.004.
相似文献/References:
[1]周玉祥,蓝博文,黄春榆,等.64排螺旋CT冠状动脉血管成像诊断冠状动脉-肺动脉瘘的应用价值[J].国际放射医学核医学杂志,2016,40(1):26.[doi:10.3760/cma.j.issn.1673-4114.2016.01.006]
Zhou Yuxiang,Lan Bowen,Huang Chunyu,et al.Clinical value of coronary artery-pulmonary artery fistula revealed by 64-slice spiral CT coronary angiography[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):26.[doi:10.3760/cma.j.issn.1673-4114.2016.01.006]
[2]陈超坤,刘亮,傅飞先,等.囊性胸腺瘤和囊性畸胎瘤的影像学特征及鉴别诊断[J].国际放射医学核医学杂志,2016,40(1):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
Chen Chaokun,Liu Liang,Fu Feixian,et al.Imaging features and differential diagnosis of cystic thymoma and cystic teratoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
[3]岳进,苏丽萍.全身MRI与PET/CT在淋巴瘤骨髓浸润诊断及预后中的作用[J].国际放射医学核医学杂志,2016,40(1):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
Yue Jin,Su Lipin.Function of whole-body MRI and PET/CT in the diagnosis and prognosis of lymphoma with bone marrow infiltration[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
[4]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[5]麦卫平,张永林.能谱CT成像在肺癌诊断中的应用研究进展[J].国际放射医学核医学杂志,2016,40(1):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
Mai Weiping,Zhang Yonglin.Research progress of spectral imaging in the diagnosis of lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
[6]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[7]周翠屏,廖俊杰,何国华,等.原发性肠系膜巨大淋巴结增生症的MSCT表现与病理对照分析[J].国际放射医学核医学杂志,2016,40(3):175.[doi:10.3760/cma.j.issn.1673-4114.2016.03.003]
Zhou Cuiping,Liao Junjie,He Guohua,et al.Primary mesenteric Castleman disease:MSCT findings with histopathologic correlation[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):175.[doi:10.3760/cma.j.issn.1673-4114.2016.03.003]
[8]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[9]张巧娜,刘汉东.上颌窦上皮-肌上皮癌的CT表现一例[J].国际放射医学核医学杂志,2016,40(3):237.[doi:10.3760/cma.j.issn.1673-4114.2016.03.015]
[10]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[11]胡斌,王锦锋,毛秋粉.18F-FDG PET/CT显像在Tg阳性131I全身显像阴性的分化型甲状腺癌患者中的应用价值[J].国际放射医学核医学杂志,2015,39(3):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
Hu Bin,Wang Jinfeng,Mao Qiufen.The application value of 18F-FDG PET/CT in patients with differentiated thyroid cancer of high thyroglobulin level and negative 131I whole body scan[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
[12]汤敏敏,刘建中,武志芳,等.分化型甲状腺癌患者131I治疗后体内残留放射性活度的评估[J].国际放射医学核医学杂志,2014,38(6):363.[doi:10.3760/cma.j.issn.1673-4114.2014.06.004]
Tang Min-min,Liu Jian-zhong,Wu Zhi-fang,et al.Estimation of residual activities in patients with differentiated thyroid cancer after administration of 131I for therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):363.[doi:10.3760/cma.j.issn.1673-4114.2014.06.004]
[13]常伟,高再荣.甲状腺癌分子影像诊断与靶向治疗研究进展[J].国际放射医学核医学杂志,2009,33(4):218.[doi:10.3760/cma.j.issn.1673-4114.2009.04.008]
CHANG Wei,GAO Zai-rong.Advances on molecular imaging diagnosis and targeted therapy of thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(6):218.[doi:10.3760/cma.j.issn.1673-4114.2009.04.008]
[14]咸雨蔚,左书耀.甲状腺肿瘤SPECT-CT融合显像的应用近况[J].国际放射医学核医学杂志,2006,30(3):157.
XIAN Yu-wei,ZUO Shu-yao.Fusion images of SPECT-CT in the application of thyroid neoplasms[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(6):157.
[15]冯学民.甲状腺癌的影像学研究进展[J].国际放射医学核医学杂志,2006,30(5):275.
FENG Xue-min.Advances in imaging diagnosis of thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(6):275.